Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland
Multiple sclerosis (MS) has significant financial consequences for healthcare systems, individual patients and households, and the wider society. This study examines the distribution of MS costs and resource utilisation across cost categories and from various perspectives, as MS disability increases.
Two hundred and fourteen patients with MS were recruited from a specialist MS outpatient clinic in Ireland and included in an interview-based study on MS-related healthcare resource consumption and costs. Patients were grouped into three categories based on disability: mild [Expanded Disability Status Scale (EDSS) score 0–3.5, n = 114], moderate (EDSS 4.0–6.5, n = 72) and severe (EDSS 7.0–9.5, n = 27). The mean annual direct and indirect costs (in year 2012 values) were estimated using non-parametric bootstrapping.
Participants were 66.4 % female, with a mean age of 47.6 years and a mean EDSS score of 3.6. The majority had relapsing-remitting MS (RRMS) (53 %). The mean annual direct (indirect) costs per person were €10,249 (€9,447), €13,045 (€31,806) and €56,528 (€39,440) in mild, moderate and severe MS, respectively. Direct costs are driven by the cost of disease-modifying therapies and professional home help in mild and severe MS, respectively. Between 74 % (severe MS) and 96 % (mild MS) of all direct costs are borne by the healthcare payer, the remainder being incurred by patients, their families or other non-healthcare organisations.
MS is associated with high levels of healthcare resource consumption and costs, and these costs increase with increasing disability. There is potential to significantly reduce the economic burden of MS through interventions that prevent progression from mild or moderate MS to severe MS, help support independent living at home and keep people with MS in the work force.
KeywordsMultiple Sclerosis Indirect Cost Direct Cost Expand Disability Status Scale Informal Care
We have no conflicts of interest. No funding was received for this study.
The study was conceptualised and initiated by EF. All authors contributed to the study design. Data acquisition was conducted by EF, NT and CMcG. EF and CW performed the study analyses. EF drafted the manuscript. All authors contributed to revisions of the manuscript and critically revised the manuscript for intellectual content. EF is the guarantor for the overall content.
- 3.WHO and MSIF, Atlas: multiple sclerosis resources in the world. London: Multiple Sclerosis International Federation, 2008. Available at: http://www.msif.org/en/about_msif/what_we_do/atlas_of_ms/index.html. Accessed 31 July 2013.
- 5.Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N. Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Mult Scler. 2013. doi: 10.1177/1352458512474860.
- 12.Casado V, Martinez-Yelamos S, Martinez-Yelamos A, Carmona O, Alonso L, Romero L et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Services Research. 2006;6.Google Scholar
- 16.Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2009;374(9700):1503–11.CrossRefGoogle Scholar
- 18.Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. 2nd ed. London: Gaskell; 2001.Google Scholar
- 20.Department of Finance (An Roinn Airgeadais) Ireland. Test discount rate. 2010. Available at: http://www.finance.gov.ie/viewdoc.asp?DocID=5387. Accessed 31 July 2013.
- 21.Central Statistics Office. Earnings and labour costs. Ireland: Central Statistics Office; 2013.Google Scholar
- 23.The Multiple Sclerosis Society of Ireland. http://www.ms-society.ie/pages/living-with-ms. Accessed 31 July 2014.
- 24.Health Service Executive Primary Care Reimbursement Service (HSE-PCRS). Statistical analysis of claims and payments 2011. Dublin 2012.Google Scholar
- 25.Association of British Neurologists. Revised (2009) Association of British neurologists’ guidelines for prescribing in multiple sclerosis. London; 2009.Google Scholar
- 26.Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRefGoogle Scholar
- 31.Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013. doi: 10.3111/13696998.2013.807267.
- 32.OECD Average Annual Wages. 2011. Available at: http://stats.oecd.org/Index.aspx?DataSetCode=AV_AN_WAGE. Accessed 13 June 2013.
- 33.Health Service Executive (HSE) Casemix Unit: ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2010 costs and activity. 2012.Google Scholar
- 34.Nursing home support scheme cost of care in public nursing homes. 2011. Available at: http://www.hse.ie/eng/services/list/4/olderpeople/nhss/costhse.pdf. Accessed 13 June 2013.
- 35.Nursing homes support scheme maximum agreed prices with private and voluntary nursing homes. 2012. Available at: http://www.irishnursinghomes.ie/CostofCarePrivateandVoluntaryNursingHomes.pdf. Accessed 13 June 2013.
- 37.Consolidated salary scales in accordance with financial emergency measures in the public interest (No. 2) Act 2009 (No. 41 of 2009). Available at: http://www.hse.ie/eng/staff/Benefits_Services/pay/Payscalesjan2010.pdf. Accessed 13 June 2013.
- 38.Primary care reimbursement service. Reimbursable items. http://www.sspcrs.ie/druglist/search.jsp. Accessed 13 June 2013.